Routine vaccination with polysaccharide meningococcal vaccines is an ineffective and possibly harmful strategy
نویسندگان
چکیده
1 Coordinator, Vaccines Assessment and Monitoring, Department of Vaccines & Biologicals, World Health Organization, Geneva, Switzerland. Correspondence should be sent to this author (e-mail: [email protected]). 2 Immunization Advisor, World Health Organization, Kampala, Uganda. 3 Global Alert and Response, Department of Communicable Disease Surveillance and Response, World Health Organization, Geneva, Switzerland. 4 Scientist, Vaccines Assessment and Monitoring, Department of Vaccines & Biologicals, World Health Organization, Geneva, Switzerland. 5 Director, Division of Prevention and Control of Communicable Diseases, WHO Regional Office for Africa, Harare, Zimbabwe. 6 Senior Policy Advisor to the Director-General and Director, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland. Round Table Discussion
منابع مشابه
Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
In January 2005, a tetravalent meningococcal polysaccharide-protein conjugate vaccine ([MCV4] Menactra, manufactured by Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was licensed for use among persons aged 11-55 years. CDCns Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of young adolescents (defined in this report as persons aged 11-12 years) with MCV4 at ...
متن کاملGlobal practices of meningococcal vaccine use and impact on invasive disease.
A number of countries now include meningococcal vaccines in their routine immunization programs. This review focuses on different approaches to including meningococcal vaccines in country programs across the world and their effect on the burden of invasive meningococcal disease (IMD) as reflected by pre and post-vaccine incidence rates in the last 20 years. Mass campaigns using conjugated menin...
متن کاملMeningococcal polysaccharide vaccine failure in a patient with C7 deficiency and a decreased anti-capsular antibody response.
A 20-y-old male presented with symptoms of meningococcal sepsis and died despite appropriate medical interventions. Blood cultures grew N. meningitidis serogroup Y. The patient had received the meningococcal quadrivalent (A,C,W-135,Y) polysaccharide vaccine 15 mo previously. Because the patient had a history of meningococcal meningitis at age 10, archived serum was obtained for further analysis...
متن کاملMucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants.
BACKGROUND Serogroup C meningococcal conjugate polysaccharide vaccines have been reported to induce significant serum IgG antibodies and immunologic memory in infants. Because meningococcus is a mucosal pathogen colonizing the nasopharynx, local mucosal immune responses may play an important role in host defense against infection and carriage. We have investigated the mucosal IgA and IgG antibo...
متن کاملThe meningococcus tamed?
Serogroup B Neisseria meningitidis is a frequent cause of invasive meningococcal disease, yet there are no effective vaccines suitable for routine immunisation. Limited efficacy has been shown with meningococcal outer membrane vacccines in children 4 years and older. Here we review the status of current research and consider new approaches to development of meningococcal serogroup B vaccines.
متن کامل